Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
about
Risperidone (depot) for schizophreniaLong-term outcomes of antipsychotic treatment in patients with first-episode schizophrenia: a systematic reviewRandomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternativesComparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyLong-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designsEffectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesAlmost all antipsychotics result in weight gain: a meta-analysis.Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Long-term efficacy and tolerability of quetiapine in patients with schizophrenia who switched from other antipsychotics because of inadequate therapeutic response-a prospective open-label study.Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in JapanPaliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia.Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.Progress in compliance research and intervention: a commentary.Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.Olanzapine pamoate for the treatment of schizophrenia.Schizophrenia guidelines across the world: a selective review and comparison.Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia.Antipsychotic switching in schizoaffective disorder: A systematic review.Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.Adherence to Medication Regimen in Patients with Severe and Chronic Psychiatric Disorders: A Qualitative Study.Antipsychotic medication and long-term mortality risk in patients with schizophrenia; a systematic review and meta-analysis.Risperidone long-acting injection and 1-year rehospitalization rate of schizophrenia patients: A retrospective cohort study.Once-monthly paliperidone palmitate in early stage schizophrenia - a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia.Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).Functional recovery results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE).Long-acting injectable risperidone and oral antipsychotics in patients with schizophrenia: results from a prospective, 1-year, non-interventional study (InORS).Healthcare cost reductions associated with the use of LAI formulations of antipsychotic medications versus oral among patients with schizophrenia.
P2860
Q24185901-0688BB62-3877-4814-A5E5-2C15DBBCAA8FQ26770497-BC18CB69-0E90-4183-9B7E-FFCF3B5E00A9Q26863435-C4F6C55A-20D2-476A-8BEC-1CD0E572737CQ27320151-63D0975D-FB80-4030-BFA5-F3B423EC9D95Q28085407-CF1DA880-434A-4AD4-83AE-0657FF4C4AF0Q30542486-0301C5C1-022F-4CDC-9C97-DC915B59F7D2Q30937746-29A3419B-595E-42C9-9503-1EEF7505A132Q31038656-84D1829B-D8B7-4D30-A4E0-72EFB8DB58BAQ33619940-905C803E-AA57-41F2-8C9C-5D2E9A2180E5Q33650097-99AFA01F-2C87-4A2F-8C5B-E61561E08810Q34315836-BB09CC41-EDDD-4B5A-8F85-6FD3DAE493C6Q34418847-C830D93B-14E2-4A94-A289-8FA71A4A896EQ34588656-F5F8FABB-509C-401F-9BBD-9BA663A9A2C2Q34661499-32E0E08A-6AF7-4ABA-92CE-D70EFECC4BA8Q34775426-16201B87-B8F7-4015-8EE6-DDE22FDC723DQ35021026-A07CCE82-A642-476D-B67C-586513CB73CEQ35659829-0CFC8659-607F-414F-98AC-CB1FEEFB2AA9Q36144552-FE0A4071-0989-43CE-9BD7-FC3B2FF3F72FQ36798150-420BA03D-3843-43E8-A1B9-7C169C23C922Q37236148-421E826C-828A-44A7-BA29-C494FE7BE0E7Q37236153-996ABBF3-BBCE-42EC-AD2B-D1BE45856D37Q37341552-7117B5D3-696C-4B4C-A50B-27F15E7B6176Q37425054-FEC8DC4D-2B3D-4F83-99CC-269C486F1826Q37451403-5BDEF371-E9BE-44BB-86AD-0986E7A80EC4Q37831310-43B36B25-B123-4717-80D0-D1669C931429Q37949405-00314620-40B5-496C-A2F9-B3A365A40C8EQ38086645-282554F0-851C-4AA3-A0DC-B89B9D8E049CQ38115487-A572B85A-DAB5-4561-8758-189735B9213CQ38206231-B786E77D-5F6A-4CB2-A537-D7B41F9951ABQ38370545-89DD5623-3874-4C98-BAC9-7AB446FBD8ECQ38473914-A8D4D7D1-CE1A-4C13-B801-4C78CE14A819Q39145621-8AAE526F-02EB-4AFD-B986-E5B68BE6CC52Q39233778-85376A32-4024-452C-8927-B838C4238CE1Q41204400-66018BCC-E5EF-4168-B99E-69BCD786E1EAQ41634413-186BD0D5-0344-44F5-91C1-7AF0F1124DAAQ41656775-089E794B-E626-4066-A78C-9539C861B3D7Q41899147-8222B2D5-AFB4-481B-8A20-1A8E025267D7Q43694540-612273E2-0A8C-4EEB-96E7-7B760B69452AQ45170470-9120730E-BCB6-4C29-9D60-7D6E77ADE7E7Q45747274-79699325-7B14-4766-A608-D5272DEE801D
P2860
Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Relapse prevention in schizoph ...... el, randomized clinical trial.
@ast
Relapse prevention in schizoph ...... el, randomized clinical trial.
@en
Relapse prevention in schizoph ...... el, randomized clinical trial.
@nl
type
label
Relapse prevention in schizoph ...... el, randomized clinical trial.
@ast
Relapse prevention in schizoph ...... el, randomized clinical trial.
@en
Relapse prevention in schizoph ...... el, randomized clinical trial.
@nl
prefLabel
Relapse prevention in schizoph ...... el, randomized clinical trial.
@ast
Relapse prevention in schizoph ...... el, randomized clinical trial.
@en
Relapse prevention in schizoph ...... el, randomized clinical trial.
@nl
P2093
P2860
P356
P1476
Relapse prevention in schizoph ...... el, randomized clinical trial.
@en
P2093
Andreas Schreiner
Frédéric Rouillon
Joachim Cordes
Lars Eriksson
Paul Bergmans
Rosario de Arce
Wolfgang Gaebel
P2860
P2888
P304
P356
10.1038/NPP.2010.111
P407
P577
2010-08-04T00:00:00Z
P6179
1046929112